Arcturus Therapeutics Holdings Inc. (ARCT) earnings
ARCT earnings moved a median of -2.02% by the close. Quarterly and annual ARCT reports and results, each read against the price at its own news timestamp. Back to the ARCT overview →
22 measured ARCT earnings events.
Where these ARCT earnings landedvs 20 measured ARCT earnings reactions
| Middle 50% of ARCT earnings reactions | -7.27% to +0.71% |
|---|---|
| Median reaction (to close) | -2.02% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ARCT earnings events with a measured close landed between -7.27% and +0.71%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress | Press release | +1.07% | +13.82% | |
| Form 10-Q Arcturus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +1.07% | +13.82% | |
| Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress | Press release | -0.36% | +12.16% | |
| Form 10-Q Arcturus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -0.36% | +12.16% | |
| Form 10-K Arcturus Therapeutics For: Dec 31 | SEC filing · Form 10-K | -6.33% | +0.93% | |
| Form 10-Q Arcturus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +0.06% | -5.36% | |
| Form NT 10-Q Arcturus Therapeutics For: Sep 30 | SEC filing · Form NT | +0.06% | -5.36% | |
| Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress | Press release | +3.89% | -2.03% | |
| Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress | Press release | +3.99% | — | |
| Form 10-Q Arcturus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +3.99% | — | |
| Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress | Press release | +5.47% | -7.27% | |
| Form 10-Q Arcturus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +5.47% | -7.27% | |
| Form 10-K Arcturus Therapeutics For: Dec 31 | SEC filing · Form 10-K | +2.42% | -1.69% | |
| Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress | Press release | +1.33% | +0.64% | |
| Form 10-Q Arcturus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +1.33% | +0.64% | |
| Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress | Press release | +0.00% | -11.28% | |
| Form 10-Q Arcturus Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -11.28% | |
| Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress | Press release | -1.84% | -7.88% | |
| Form 10-Q Arcturus Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.84% | -7.88% | |
| Form 10-K Arcturus Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.61% | -3.01% | |
| Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress | Press release | +5.74% | -2.00% | |
| Form 10-Q Arcturus Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +5.74% | -2.00% |
Keep exploring
More ARCT: analyst actions → · SEC filings → · ARCT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
| Rigel Pharmaceuticals, Inc. (RIGL) | 281 | -0.46% | 42% |
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
| Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) | 278 | -0.48% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.